According to a phase I/II study published in The Lancet Haematology, melflufen is active in patients with relapsed and refractory multiple myeloma (MM) and tolerable in most patients.1
Researchers indicated that these results show the feasibility of this regimen and support the development of additional studies of melflufen in multiple myeloma, both in combination with dexamethasone (Ozurdex) as well as in triplet regimens with additional classes of drugs.
“We are excited to share with the scientific community these findings from our phase I/II study of our peptide-drug conjugate, melflufen. The results published today served as the foundation of our broad clinical development program,” Klaas Bakker, MD chief medical officer at Oncopeptides, said in a press release.2 “We recognize the significant unmet needs of patients with relapsed and refractory MM who currently have few…
